Tamoxifen Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg and 20 mg
Reference Brands: Nolvadex(US & EU)
Category:
Oncology Cancer Care
Tamoxifen is an oncology drug used for breast cancer treatment and prevention, available in 10 mg and 20 mg oral tablet strengths in the U.S. and EU. Under the brand name Nolvadex, it blocks estrogen’s effects on estrogen receptor-positive (ER+) breast cancer. Tamoxifen is essential in adjuvant therapy and for preventing breast cancer in high-risk patients, with both branded and generic versions available for B2B pharmaceutical distribution.
Tamoxifen is available in Tablets
and strengths such as 10 mg and 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tamoxifen is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tamoxifen can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tamoxifen is a widely used oncology drug for breast cancer treatment and prevention, primarily available as oral tablets in 10 mg and 20 mg strengths in the U.S. and EU. Under the brand name Nolvadex, Tamoxifen is a selective estrogen receptor modulator (SERM), effective in treating estrogen receptor-positive (ER+) breast cancer by blocking estrogen’s growth-promoting effects. It is available in both U.S. and EU markets with generic alternatives. Tamoxifen plays a critical role in adjuvant therapy and breast cancer prevention for high-risk patients. Its availability in oral form makes it suitable for B2B pharmaceutical distribution.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing